Total Body Irradiation
Phase 2Small molecule
Total Body Irradiation is one of 85 small molecule programs targeting TED. It is currently in Phase 2.
3
Indications
7
Total Trials
4
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
98 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
PIASKY
RochePhase 3
Tepadina
Jazz PharmaceuticalsPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignancy1 trial
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03674411·22 enrolled
Stem Cell Transplantation1 trial
Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00426517·48 enrolled
2 more indications
Chronic Granulomatous Disease1 trial
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled
Sickle Cell Disease1 trial
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
Recruiting·—·Phase 1·NCT07015684·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Total Body Irradiation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details